Wellington Management Group
OBIO icon

Wellington Management Group’s Orchestra BioMed OBIO Stock Holding History

Wellington Management Group’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-113,052
Closed -$1.13M – 2189
2021
Q4 		$1.13M Sell
113,052
-392,383
-78% -$3.87M ﹤0.01% 1780
2021
Q3 		$5M Sell
505,435
-120,938
-19% -$1.19M ﹤0.01% 1509
2021
Q2 		$6.39M Sell
626,373
-12,371
-2% -$128K ﹤0.01% 1428
2021
Q1 		$7.17M Sell
638,744
-211,256
-25% -$2.57M ﹤0.01% 1336
2020
Q4 		$10.9M Hold
850,000
– – ﹤0.01% 1170
2020
Q3 		$9.35M Buy
+850,000
New +$9.54M ﹤0.01% 1123

Other funds holding OBIO

DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AC
Amitell Capital Singapore $109M AUM 50.64% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Wellington Management Group's OBIO Position: Q1 2022 in Review

Wellington Management Group sold out of Orchestra BioMed (OBIO) in Q1 2022, closing a stake of 113,052 shares — an estimated $1.13M sold.

Wellington Management Group first reported a position in OBIO in Q3 2020 and held it in 6 quarters. The position peaked at $10.9M in Q4 2020. 59 funds tracked by Wall St. Rank hold OBIO as of Q1 2022.

  • Wellington Management Group reported no remaining Orchestra BioMed position as of Q1 2022 after selling out during the quarter.
  • Wellington Management Group sold 113,052 Orchestra BioMed shares in Q1 2022, an estimated $1.13M.
  • Wellington Management Group first reported a position in Orchestra BioMed in Q3 2020 and held it in 6 quarters.
  • Wellington Management Group's Orchestra BioMed position peaked at $10.9M in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2022.

Based on Wellington Management Group's 13F filing for Q1 2022, filed 16 May 2022.